

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Recruitment and retention of participants in randomised controlled trials: a review of trials published in the National Institute for Health Research (NIHR) Journals Library (1997 – 2020)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059230
Article Type:	Original research
Date Submitted by the Author:	13-Nov-2021
Complete List of Authors:	Jacques, Richard; The University of Sheffield, School of Health and Related Research Ahmed, Rashida; The University of Sheffield, School of Health and Related Research Harper, James; The University of Sheffield, School of Health and Related Research Ranjan, Adya; The University of Sheffield, School of Health and Related Research Saeed, Isra; The University of Sheffield, School of Health and Related Research Simpson, Rebecca; The University of Sheffield, School of Health and Related Research Walters, Stephen; The University of Sheffield, School of Health and Related Research
Keywords:	STATISTICS & RESEARCH METHODS, AUDIT, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Recruitment and retention of participants in randomised controlled trials: a review of
4 trials published in the National Institute for Health Research (NIHR) Journals Library
5 (1997 – 2020)
6
7
8
9
10

11 Richard M Jacques, Rashida Ahmed, James Harper, Adya Ranjan, Isra Saeed,
12 Rebecca M Simpson, Stephen J Walters
13
14
15

16
17
18 School of Health and Related Research, University of Sheffield, Sheffield, UK
19
20
21

22
23 Corresponding author:
24

25 Dr Richard Jacques
26

27 Email: r.jacques@sheffield.ac.uk
28
29
30
31

32 School of Health and Related Research
33

34 University of Sheffield
35

36 30 Regent Street
37
38

39 Sheffield
40
41

42 S1 4DA
43
44
45
46

47 **Word count:** 3321
48

49 **Number of figures and tables:** 3 figures, 7 tables
50

51 **Keywords:** randomised controlled trials; recruitment; retention
52
53
54
55
56
57
58
59
60

Abstract

Objectives

To review the consent, recruitment and retention rates for randomised controlled trials (RCTs) funded by the United Kingdom's National Institute for Health Research (NIHR) and published in the online NIHR Journals Library between January 1997 and December 2020.

Design

Comprehensive review.

Setting

RCTs funded by the NIHR and published in the NIHR Journals Library.

Data extraction

Information relating to the trial characteristics, sample size, recruitment and retention.

Primary and secondary outcome measures

Target sample size and whether it was achieved; recruitment rates (number of participants recruited per centre per month) and retention rates (randomised participants retained and assessed with valid primary outcome data).

Results

This review identified 388 individual RCTs from 379 reports in the NIHR Journals Library. The final recruitment target sample size was achieved in 63% (245/388) of the RCTs. The original recruitment target was revised in 30% (118/388) of trials (downwards in 67% (79/118)). The median recruitment rate (participants per centre per month) was found to be 0.95 (IQR: 0.42 to 2.60) and the median retention rate (proportion of participants with valid primary outcome data at follow-up) was estimated at 88% (IQR: 80% to 97%).

Conclusions

There is considerable variation in the consent, recruitment and retention rates in publicly funded RCTs. Although the majority of (six out of ten) trials in this review achieved their final target sample; three out of ten trials revised their original target sample size (downwards in seven out of ten trials). Investigators should bear this in mind at the planning stage of their study and not be overly optimistic about their recruitment projections.

For peer review only

Strengths and limitations of this study

- This review reports the recruitment and retention rates for 388 single and multicentre randomised controlled trials published in the National Institute for Health Research (NIHR) Journals Library between January 1997 and December 2020. It is the largest comprehensive review of recruitment and retention in trials to date.
- The NIHR Journals Library intends to publish all research from Efficacy and Mechanism Evaluation (EME), Health Services and Delivery Research (HS&DR), Health Technology Assessment (HTA), Programme Grants for Applied Research (PGfAR) and Public Health Research (PHR) funded projects. This study therefore has less chance of publication bias compared to a review of other journals where publishing is more selective.
- The calculation of recruitment rates was limited by the information reported. For some trials crude recruitment rates, assuming all centres were recruiting for the same time period, were calculated, these estimates may be an underestimation of the true recruitment rate.
- The review is restricted to publicly funded trials published in the NIHR Journals Library, which may limit the generalisability of the findings.

Introduction

Randomised Controlled Trials (RCTs) are the 'gold-standard' research design for evaluating the effectiveness of interventions in health, education and policy.(1) Conducting an RCT requires major financial investment and substantial amounts of public funding is spent in this area each year. In 2019/2020 the National Institute for Health Research (NIHR) in England awarded over £250 million of funding to 310 research projects with a substantial proportion of this invested in RCTs.(2)

There are many practical challenges associated with conducting clinical trials. The leading reason for premature discontinuation of RCTs is poor recruitment of participants (3,4) with accrual often taking longer or being more difficult than expected. Poor recruitment can have a number of consequences including the study being underpowered if the target sample size is not met and increased costs if an extension is required.(5) Furthermore discontinued RCTs are less likely to be published in medical journals (3) which has ethical implications around research waste.(6)

There have been a number of previous studies in the United Kingdom (UK) investigating recruitment and retention in publicly funded RCTs. The earliest review, a cohort of trials funded by the Medical Research Council (MRC) and NIHR Health Technology Assessment (HTA) between 1994 and 2002, reported that 31% (38/122) of the trials successfully recruited to their original recruitment target, with 54% (65/122) of trials awarded a grant extension.(7) There is evidence of a marginal improvement in these figures over time, with results from a cohort of 151 RCTs funded by the NIHR HTA programme between 2004 and 2016 finding that 40% (61/151) of trials successfully recruited to their original sample size, and 32% (49/151) of trials extended their recruitment.(8) In the same study the median recruitment rate was found to be 0.92 (IQR: 0.43-2.79) participants per centre per month.

Following the publication of the review by Walters *et al.*(8) in 2017 there have been several Cochrane systematic reviews looking at strategies for improving recruitment (9) and retention (10) of participants in RCTs. Two strategies for improving

1
2
3 recruitment were identified with high-certainty evidence: using open trials rather than
4 blinded, placebo controlled trials, and telephone reminders to people who did not
5 respond to postal invitations. There has also been a systematic review of statistical
6 models for predicting recruitment at the design stage of a clinical trial (11) but a
7 survey of statisticians in UK and European clinical trial networks found that 90%
8 (62/69) did not use statistical models for recruitment prediction.(12) In 2014 a trials
9 methodology research priority setting exercise was conducted using a Delphi survey
10 of directors of UK Clinical Research Collaboration registered Clinical Trials Units.(13)
11 Two of the three highest priority areas were 'Research methods to boost recruitment
12 in trials' and 'Methods to minimise attrition'.
13
14
15
16
17
18
19
20
21

22 The Consolidated Standards of Reporting Trials (CONSORT) statement was first
23 published in 1996 (14), and revised in 2001 (15) and 2010.(16) It is a checklist of
24 standards for reporting how a trial was designed, analysed and interpreted, and it
25 has been endorsed both by prominent general medical journals and many specialist
26 medical journals.(17) However, reporting guidelines such as CONSORT are not
27 adopted and adhered to as much as they should be (18) with the previous review of
28 recruitment and retention in RCTs by Walters *et al.*(8) finding that 63% (95/151) of
29 trials demonstrated complete compliance with CONSORT statement and reported
30 each of the number: screened, eligible, declined consent, recruited and assessed for
31 their primary outcome.
32
33
34
35
36
37
38
39
40

41 This review aims to update previous research on how well recruitment and retention
42 figures are reported, and the rates of recruitment and retention in trials published in
43 the NIHR HTA journal between January 2004 and April 2016.(8) In this study, we
44 update and extend this review to look at trials published in the NIHR Journals library
45 from January 1997 to December 2020.
46
47
48
49
50

51 **Methods**

52 **Trial Identification**

53 Reports of individually RCTs published in the NIHR Journals Library from January
54 1997 to December 2020 were reviewed. Established in 2006, the NIHR is now the
55 largest funder of health and social research in England. The NIHR Journals Library
56
57
58
59
60

1
2
3 publishes five peer reviewed journals reporting the results from a range of health
4 research areas: Efficacy and Mechanism Evaluation (EME), Health Services and
5 Delivery Research (HS&DR), Health Technology Assessment (HTA), Programme
6 Grants for Applied Research (PGfAR) and Public Health Research (PHR)
7
8 (<https://www.journalslibrary.nihr.ac.uk/journals/>). The first volume of the HTA journal
9
10 was published in 1997 whereas the other four journals are more recent with the first
11 volumes of the HS&DR, PGfAR and PHR journals published in 2013 and the first
12 volume of the EME journal published in 2014. Trial reports published in the NIHR
13 Journals Library were chosen as they provide a detailed description of the research
14 methods and study results including recruitment and retention information.
15
16
17
18
19
20
21

22 The reports for review were obtained from the NIHR Journals Library website
23 (<https://www.journalslibrary.nihr.ac.uk/> - last accessed 10 November 2021) along
24 with any published trial paper, protocol paper or trial protocol. The published
25 International Standardised Randomised Controlled Trial Number (ISRCTN) was
26 used where available to check the ISRCTN register of clinical trials for additional
27 information (<https://www.isrctn.com/>). The titles and abstracts of all reports published
28 in the five NIHR journals from 1st January 1997 to 31st December 2020 were
29 checked for relevance.
30
31
32
33
34
35
36
37

38 **Inclusion/Exclusion Criteria**

39 To ensure consistency the eligibility criteria used by Walters *et al.*(8) was adopted.
40 Reports included in the review were of single or multicentre RCTs that were either
41 fully or partially randomised and where recruitment to the trial had finished. Reports
42 of trials that terminated early, either prior to completion of recruitment or following
43 recruitment but prior to completion of follow-up were retained. Reports of two or
44 more parallel RCTs were included as were nested parallel trials as part of another
45 RCT. Some reports in the PGfAR journal included multiple independent RCTs and
46 each of these trials were included separately. Reports of non-RCTs, cluster RCTs,
47 pilot/feasibility studies, adaptive designs, influenza vaccination trials, follow-on
48 studies and ongoing RCTs that had not completed recruitment were excluded.
49 Reports of internal pilot trials that either went on to a full trial or were terminated due
50 to recruitment issues were included in the review.
51
52
53
54
55
56
57
58
59
60

Data Extraction

After the NIHR reports had been selected for inclusion, information was extracted using a standardised data extraction form. For each of the included trials the following information was extracted.

- Trial characteristics, including the trial design, clinical area, type of intervention, type of control, number of arms, use of blinding of trial participant, geographical region, number of centres, any support provided by a Clinical Trials Unit (CTU) and whether there was any description of pilot or feasibility work done prior to the start of the trial.
- Sample size, recruitment and retention information, including the target and actual sample size, the overall and centre-specific recruitment period and CONSORT information on the numbers screened, consented, randomised and analysed for the primary outcome.(16)

The selection of RCTs and data extraction was conducted by a team of reviewers (RMJ, RA, JH, AR and IS). Three reviewers (RMJ, RMS and SJW) conducted quality assurance checks on 30% of the included trials after the data extraction was completed, and disagreements were discussed to achieve consensus.

Analysis

The primary outcome for the review was the recruitment rate for each trial. This was defined as the number of participants recruited and randomised per centre per month. Where explicit dates were reported the recruitment rate was calculated as the time between the date of recruitment start and the date of recruitment completion. In cases where only the months of recruitment were reported the recruitment period was estimated as the time between the 1st of the month and the end of the final month. If the date of the first participant recruited was reported instead of the start date of recruitment then the start of recruitment was taken as the 1st of the month of the first participant recruited. When the start of recruitment was not reported the start

1
2
3 of screening was used to calculate the recruitment period. The recruitment period
4 was estimated by subtracting the length of the follow-up period from the length of the
5 study period when explicit information on the start and end of recruitment was not
6 reported.
7
8
9

10
11 The recruitment rate was calculated in two different ways. The overall recruitment
12 rate was calculated as the total number of participants recruited divided by the
13 maximum number of recruiting sites, then divided by the total number of months that
14 the trial recruited for. This overall recruitment rate is likely to be an underestimate for
15 multicentre trials because each trial site is unlikely to open for recruitment at the
16 same time and will not recruit for the entire recruitment period. To allow for the
17 difference in start-up times and recruitment periods between sites, where available,
18 the site-specific recruitment periods were extracted. These were averaged over the
19 number of sites to give an average site-specific recruitment period. The average
20 recruitment rate was calculated as the total number of participants recruited divided
21 by the maximum number of sites, then divided by the average number of months that
22 the trial recruited for.
23
24
25
26
27
28
29
30
31
32
33

34 Recruitment rates were summarised using the median and interquartile range (IQR)
35 due to the skewed distribution of the data.⁽¹⁹⁾ The median and IQR were also used
36 to summarise the secondary outcomes of the percentage of eligible participants
37 consented and randomised and the percentage of eligible participants retained and
38 assessed in the primary outcome of the trial. Comparisons of recruitment and
39 retention rates were made between different trial characteristics using appropriate
40 non-parametric tests; Mann-Whitney U test (for characteristics with two levels),
41 Kruskal-Wallis test (three or more nominal levels) and Jonckheere-Terpstra test
42 (three or more ordered levels). Analysis was conducted on a complete case basis so
43 where the characteristics information, recruitment rate or retention rate were missing
44 these were excluded. All statistical analysis was conducted in R version 4.1.0 (20),
45 figures were produced using the package ggplot2 (21), and the Jonckheere-Terpstra
46 test conducted using the package clinfun.⁽²²⁾
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patients and public involvement

Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Results

Between 1st January 1997 and 31st December 2020, 1899 reports were published in the five NIHR journals. Following screening, 1299 of these were excluded as reports of non-RCTs. The search identified 600 reports of RCTs of which 221 were excluded after applying the exclusion criteria (101 cluster RCTs; 95 pilot/feasibility RCTs; 14 follow-on studies; 6 adaptive designs; 3 influenza vaccination trials; and 2 ongoing trials). Some publications reported the results of multiple independent trials, therefore in total, 388 individual RCTs from 379 reports were included in the review and analysed as shown in Figure 1. This includes 151 RCTs from the review by Walters *et al.*(8).

Trial Characteristics

The characteristics of the 388 trials included in the review are summarised in Table 1. The most common design was a two arm parallel group, multicentre RCT. The most frequently studied clinical areas were mental health, including psychiatry and psychology (19% (73/388) of trials) and musculoskeletal conditions, including orthopaedics, rheumatology and back pain (11% (44/388) of trials). The majority of trials were set in hospitals (56% (219/388)), took place in the UK (91% (355/388)) and across multiple geographic regions (82% (317/388)). Trials of pharmaceutical interventions (29% (112/388)) were more common than other interventions and 78% (301/388) of trials used an active control. Half of all trial reports (194/388) reported or mentioned work from a pilot or feasibility study.

The recruitment and sample size characteristics of the RCTs included in the review are summarised in Table 2. The majority of trials (353/388) were multicentre with a median of 17 centres (IQR: 7 to 37). The final recruitment target (sample size) ranged from 44 participants to 46,000 participants and the final number recruited ranged from 2 participants to 47,062. The RCT with the highest final recruitment

1
2
3 target and highest number recruited was an obstetrics trial investigating
4 computerised interpretation of fetal heart rate during labour.(23) There were four
5 trials that recruited less than ten participants, two were discontinued at the end of an
6 internal pilot phase due to low recruitment (24,25) and the remaining two had no pilot
7 phase.(26,27) Overall, 63% (245/388) of trials recruited to their final recruitment
8 target and a further 22% (86/388) recruited to within 80% of their final recruitment
9 target. The original recruitment target was revised in 30% (118/388) of trials
10 (downwards in 67% (79/118)). For the majority of trials the primary outcome was
11 collected at between 1 and 18 months post-randomisation.
12
13
14
15
16
17
18
19

20 **CONSORT and Recruitment Data**

21
22 Summaries of the data completeness in relation to the CONSORT statement,
23 recruitment and retention are presented in Table 3. Of the 388 RCTs identified, 68%
24 (265/388) fully complied with the CONSORT statement and reported the number of
25 participants screened, eligible, declined consent, recruited and assessed for the
26 primary outcome. The total number of participants recruited and randomised, and the
27 number included in the analysis of the primary outcome, used to measure retention,
28 was available for all 388 trials. Regarding the information required to calculate the
29 recruitment rate, 98% (379/388) of trials reported the number of centres, 95%
30 (369/388) reported the maximum length of the recruitment period, and 25% (97/388)
31 reported the centre-specific recruitment information used to calculate an average
32 recruitment period per centre. There was enough information reported to calculate
33 the overall recruitment rate for 94% (365/388) of trials in this review.
34
35
36
37
38
39
40
41
42
43
44

45 **Recruitment and Retention Rates**

46
47 From the 365 trials with sufficient information to calculate the recruitment rate, the
48 median was found to be 0.95 participants recruited per centre per month. The
49 highest recruitment rate (57.75 participants per centre per month) was in a trial
50 comparing medical to surgical termination of pregnancy (28) and the lowest (0.01
51 participants per centre per month) was in a trial treatment for transverse myelitis.(26)
52 The 80th and 90th percentiles were found to be 3.70 and 9.47 participants recruited
53 per centre per month, respectively. From the 23 single centre trials with sufficient
54 information, the median recruitment rate was found to be 16.3 (IQR: 4.5-31.9, range:
55
56
57
58
59
60

1
2
3 1.58-57.75) participants per centre per month compared with a median of 0.86 (IQR:
4 0.40-2.15, range: 0.01-51.1) participant per centre per month in the 342 multi-centre
5 trials. Figure 2 shows the distribution of recruitment rates by clinical area. The
6
7 highest median recruitment rate was for dentistry (1.95 participants recruited per
8 centre per month) but this was only from five trials. The largest recruitment rates
9
10 were found to be from four obstetrics and gynaecology trials (23,28–30), a mental
11 health trial (31), and three trials from other clinical areas (32–34). A median of 72%
12 (IQR: 50-88%) of eligible participants were consented and randomised. The median
13 retention rate (percent of randomised participants retained and assessed in the
14 analysis of the primary outcome) was found to be 88% (IQR: 80-97%). There were
15 four trials (24,25,27,35) with a retention rate of 0%, these trials were all stopped
16 early due to problems with recruitment and the planned statistical analysis for the
17 primary outcome was not performed (Table 4).
18
19
20
21
22
23
24
25
26

27 The trial recruitment and retention rates are summarised by trial characteristics in
28 Tables 5 and 6 respectively. There is some statistical evidence of an association
29 between the setting of the trial, final recruitment target and the total number of
30 participants recruited but the median rates show no clear patterns to these
31 associations.
32
33
34
35
36

37 The results of the current review, in terms of successful recruitment to target sample
38 size, have been compared with three previous reviews (5,7,8) in Table 7. As this
39 review updates the findings of Walters *et al.*(8) and due to there being some overlap
40 with the trials included in Sully *et al.*(5); a column has been included for the non-
41 overlapping time interval (2017-2020) in addition to the full time interval (1997-2020).
42 Table 7 shows that 61% (107/174) of trials in the period 2017-2020 recruited 100%
43 of the original target sample size which is higher than the previous periods/reviews.
44 The target sample size was revised in 31% (54/174) of trials; and the revision was
45 downwards for 57% (31/54) of trials. An extension, to the trial timelines, was reported
46 in 37% (65/174) of trials and this was higher than the review by Walters *et al.*(8)
47 (32% (49/151)) but lower than the reviews by McDonald *et al.*(7) (54% (65/122)) and
48 Sully *et al.*(5) (45% (33/73)).
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Figure 3 shows the percentage of trials recruiting 100% of the final target and 80% or
4 more of the final target by publication year. There is no clear trend in the percentage
5 of trials recruiting 100% of the final target for the earlier years (1999-2006) but there
6 is evidence of an upward trend for the years 2007 to 2020.
7
8
9

10 11 12 13 **Discussion and Conclusions**

14
15
16 This study has systematically conducted a review of the recruitment and retention
17 data from a cohort of 388 trials published in the NIHR Journals Library between 1997
18 and 2020. This review found that the final target sample size was achieved in 63%
19 (245/388) of RCTs; the median recruitment rate was 0.95 (IQR: 0.42-2.60)
20 participants per centre per month; and the median retention rate was 88% (IQR: 80-
21 97%).
22
23
24
25
26

27
28 This review found that 53% (207/388) of publicly funded RCTs achieved their original
29 target sample size. Restricting the time period to 2017-2020 the figure is 61%
30 (107/174), this is higher than the previous figures of 55% and 40% found in the
31 reviews by Sully *et al.*(5) and Walters *et al.*(8) This is also reflected in the percentage
32 of trials recruiting to 100% of their final target where there is some evidence of an
33 upward trend for the years 2007 to 2020. However, there is still cause for some
34 concern with 30% (118/388) of trials revising their original recruitment target with the
35 majority (67% (79/118) revising the target downwards, and a third (128/338) of trials
36 having an extension to their recruitment period. These findings remain consistent
37 with the concerns expressed by clinical trials unit directors.(13)
38
39
40
41
42
43
44

45
46 The median retention rate is consistent with the result of Walters *et al.*(8) This
47 retention figure may be an overestimate as it will be affected by trials using time to
48 event outcomes, where missing outcomes are censored at the time of loss to follow-
49 up but included in analyses using survival models. The target sample size for any
50 trial should allow for participant withdrawals and loss to follow-up (36) with the
51 expected withdrawal proportion obtained from reports of studies conducted in the
52 same clinical area.(19) However, if no such information is available then a pragmatic
53 approach would be to take the proportion to be at least 10%.
54
55
56
57
58
59
60

1
2
3 This study has the following limitations. First, the review was restricted to publicly
4 funded trials published in the NIHR Journals Library, which may limit the
5 generalisability of the findings. However, as the NIHR Journals Library intends to
6 publish all research from EME, HS&DR, HTA, PGfAR and PHR funded projects, it
7 has less chance of publication bias compared to a review of other journals where
8 publishing is more selective and information related to recruitment is published in
9 less detail. Second, the data extraction was conducted by several independent
10 reviewers and although reviewers conferred to try and ensure consistency and
11 quality assurance checks were completed on a sample of reports, it is possible that
12 errors have occurred. Third, the calculation of recruitment rates was limited by the
13 information reported. For some trials centre specific recruitment information was not
14 available meaning that crude recruitment rates, assuming all centres were recruiting
15 for the same time period, were calculated. In these cases the calculated recruitment
16 rate may be an underestimate of the true recruitment rate.
17
18
19
20
21
22
23
24
25
26
27

28 This review found considerable variation in the consent, recruitment and retention
29 rates in publicly funded RCTs. Although the majority of (six out of ten) trials in this
30 review achieved their final target sample; three out of ten trials published in NIHR
31 Journals Library revised their original target sample size (downwards in seven out of
32 ten trials). Investigators should bear this in mind at the planning stage of their study
33 and not be overly optimistic about their recruitment projections.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributions

RMJ and SJW contributed to the study concept and design. RMJ, RA, JH, AR and IS contributed to the selection of data and conducted the data extraction. RMJ conducted the data analysis and drafted the manuscript. RMJ, RMS and SJW contributed to the quality assurance check of the data. All authors critically revised the manuscript and approved the final manuscript.

Funding

SJW is an NIHR Senior Investigator supported by the NIHR (NF-SI-0617-10012) for this research project. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS or the UK Department of Health and Social Care. These organisations had no role in the study design; in the collection, analysis and interpretation of the data; in writing of the report; or in the decision to submit the paper for publication.

Competing Interests

RMJ, RMS and SJW received funding across various projects from the National Institute for Health Research (NIHR).

Patient consent for publication

Not required

Ethics approval

The information extracted in this review is based on trials published in the NIHR Journals Library where ethics approvals were obtained by the original trial teams. This review does not involve recruiting new participants or analysing individual participant data, and the original participants cannot be identified from this review.

1
2
3
4 **Data availability statement**
5

6
7 The information extracted in this review is based on published trials in the NIHR
8 Journals Library. The data extracted is available upon reasonable request from the
9 corresponding author at r.jacques@sheffield.ac.uk
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

1. Torgerson DJ, Torgerson CJ. *Designing Randomised Trials in Health, Education and the Social Sciences: An Introduction*. Basingstoke: PALGRAVE MACMILLAN; 2008.
2. National Institute for Health Research Annual Report 2019/20 [Internet]. [cited 2021 Oct 11]. Available from: https://www.nihr.ac.uk/documents/about-us/our-contribution-to-research/research-performance/NIHR_Annual_Report_19_20.pdf
3. Kasenda B, von Elm E, You J, Blümle A, Tomonaga Y, Saccilotto R, et al. Prevalence, Characteristics, and Publication of Discontinued Randomized Trials. *JAMA*. 2014 Mar 12;311(10):1045–52.
4. Amstutz A, Schandelmaier S, Frei R, Surina J, Agarwal A, Olu KK, et al. Discontinuation and non-publication of randomised clinical trials supported by the main public funding body in Switzerland: a retrospective cohort study. *BMJ Open*. 2017 Jul 1;7(7):e016216.
5. Sully BGO, Julious SA, Nicholl J. A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies. *Trials*. 2013 Jun 9;14(1):166.
6. Ioannidis JPA, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, et al. Increasing value and reducing waste in research design, conduct, and analysis. *The Lancet*. 2014 Jan 11;383(9912):166–75.
7. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. *Trials*. 2006 Apr 7;7(1):9.
8. Walters SJ, Henriques-Cadby IB dos A, Bortolami O, Flight L, Hind D, Jacques RM, et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. *BMJ Open*. 2017 Mar 1;7(3):e015276.
9. Treweek S, Pitkethly M, Cook J, Fraser C, Mitchell E, Sullivan F, et al. Strategies to improve recruitment to randomised trials. *Cochrane Database Syst Rev*. 2018 Feb 22;2018(2):MR000013.
10. Gillies K, Kearney A, Keenan C, Treweek S, Hudson J, Brueton VC, et al. Strategies to improve retention in randomised trials. *Cochrane Database Syst Rev*. 2021;(3).
11. Gkioni E, Rius R, Dodd S, Gamble C. A systematic review describes models for recruitment prediction at the design stage of a clinical trial. *J Clin Epidemiol*. 2019 Nov;115:141–9.

12. Gkioni E, Dodd S, Rius R, Gamble C. Statistical models to predict recruitment in clinical trials were rarely used by statisticians in UK and European networks. *J Clin Epidemiol*. 2020 Aug 1;124:58–68.
13. Tudur Smith C, Hickey H, Clarke M, Blazeby J, Williamson P. The trials methodological research agenda: results from a priority setting exercise. *Trials*. 2014 Jan 23;15(1):32.
14. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. *JAMA*. 1996 Aug 28;276(8):637–9.
15. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet Lond Engl*. 2001 Apr 14;357(9263):1191–4.
16. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010 Mar 24;340:c332.
17. Consort Transparent Reporting of Trials [Internet]. [cited 2021 Oct 14]. Available from: <http://www.consort-statement.org/>
18. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, et al. Reducing waste from incomplete or unusable reports of biomedical research. *The Lancet*. 2014 Jan 18;383(9913):267–76.
19. Walters SJ, Campbell MJ, Machin D. *Medical Statistics: A Textbook for the Health Sciences*. 5th ed. Chichester: John Wiley & Sons, Ltd; 2021.
20. R Core Team. *R: A Language and Environment for Statistical Computing* [Internet]. Vienna, Austria; 2021. Available from: <https://www.R-project.org/>
21. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. New York: Springer-Verlag; 2016.
22. Seshan VE. *clinfun: Clinical Trial Design and Data Analysis Functions* [Internet]. 2018. Available from: <https://CRAN.R-project.org/package=clinfun>
23. Brocklehurst P, Field D, Greene K, Juszczak E, Kenyon S, Linsell L, et al. Computerised interpretation of the fetal heart rate during labour: a randomised controlled trial (INFANT). *Health Technol Assess*. 2018 Feb 13;22(9):1–186.
24. Davidson B, Gurusamy K, Corrigan N, Croft J, Ruddock S, Pullan A, et al. Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT. *Health Technol Assess*. 2020 May 1;24(21):1–38.
25. Williams NH, Jenkins A, Goulden N, Hoare Z, Hughes DA, Wood E, et al. Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC): a randomised controlled trial of adalimumab injection compared with placebo for

- 1
2
3 patients receiving physiotherapy treatment for sciatica. *Health Technol Assess.* 2017 Oct 24;21(60):1–180.
4
5
6
7 26. Absoud M, Brex P, Ciccarelli O, Diribe O, Giovannoni G, Hellier J, et al. A
8 multicentre randomised controlled TRIal of IntraVENous immunoglobulin
9 compared with standard therapy for the treatment of transverse myelitis in
10 adults and children (STRIVE). *Health Technol Assess.* 2017 May 30;21(31):1–
11 50.
12
13 27. Strang J, Kelleher M, Mayet S, Day E, Hellier J, Byford S, et al. Extended-
14 release naltrexone versus standard oral naltrexone versus placebo for opioid
15 use disorder: the NEAT three-arm RCT. *Health Technol Assess.* 2019 Feb
16 1;23(3):1–72.
17
18 28. Robson SC, Kelly T, Howel D, Deverill M, Hewison J, Lie MLS, et al.
19 Randomised preference trial of medical versus surgical termination of
20 pregnancy less than 14 weeks' gestation (TOPS). *Health Technol Assess.* 2009
21 Nov 30;13(53):1–148.
22
23 29. Morrell C, Spiby H, Stewart P, Walters S, Morgan A. Costs and benefits of
24 community postnatal support workers: a randomised controlled trial. *Health*
25 *Technol Assess.* 2000 Apr 3;4(6).
26
27 30. Townsend J, Wolke D, Hayes J, Dave S, Rogers C, Bloomfield L, et al. Routine
28 examination of the newborn: the EMREN study. Evaluation of an extension of
29 the midwife role including a randomised controlled trial of appropriately trained
30 midwives and paediatric senior house officers. *Health Technol Assess.* 2004
31 Mar 30;8(14).
32
33 31. Lobban F, Akers N, Appelbe D, Iraci Capuccinello R, Chapman L, Collinge L, et
34 al. A web-based, peer-supported self-management intervention to reduce
35 distress in relatives of people with psychosis or bipolar disorder: the REACT
36 RCT. *Health Technol Assess.* 2020 Jul 1;24(32):1–142.
37
38 32. Kinley H, Czoski-Murray C, George S, McCabe C, Primrose J, Reilly C, et al.
39 Extended scope of nursing practice: a multicentre randomised controlled trial of
40 appropriately trained nurses and pre-registration house officers in pre-operative
41 assessment in elective general surgery. *Health Technol Assess.* 2001 Jun
42 15;5(20).
43
44 33. Elliott RA, Payne K, Moore JK, Davies LM, Harper NJN, St Leger AS, et al.
45 Which anaesthetic agents and techniques are cost-effective in day surgery?
46 Literature review, national survey of practice and randomised controlled trial.
47 *Health Technol Assess.* 2003 Mar 13;6(30).
48
49 34. McDermott L, Wright AJ, Cornelius V, Burgess C, Forster AS, Ashworth M, et al.
50 Enhanced invitation methods and uptake of health checks in primary care:
51 randomised controlled trial and cohort study using electronic health records.
52 *Health Technol Assess.* 2016 Nov 14;20(84):1–92.
53
54
55
56
57
58
59
60

- 1
2
3 35. Williams CL, Weller S, Roberts L, Reading I, Cook A, Little L, et al. Timing of
4 surgical intervention for developmental dysplasia of the hip: a randomised
5 controlled trial (Hip 'Op). *Health Technol Assess*. 2017 Oct 25;21(63):1–84.
6
7
8 36. Walters S, Simpson R, Jacques R. Sample Size Estimation for Trials and Other
9 Two Group Comparisons. In: *SAGE Research Methods Cases* [Internet].
10 London; 2021. Available from: <https://www.doi.org/10.4135/9781529741636>
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Characteristics of the trials included in the review

Characteristic		n (%)
Trial Design (n=388)	Parallel	345 (89)
	Factorial	19 (5)
	Crossover	4 (1)
	Other ^A	20 (5)
Arms (n=388)	2	290 (75)
	3	61 (16)
	4	24 (6)
	>4	13 (3)
Clinical Area (n=388)	Mental Health	73 (19)
	Musculoskeletal, Orthopedics & Rheumatology	44 (11)
	Obstetrics & Gynaecology	32 (8)
	Respiratory	29 (7)
	Cardiovascular	24 (6)
	Cancer/Oncology	21 (5)
	Stroke	19 (5)
	Dermatology (including ulcers)	17 (4)
	Gastrointestinal	14 (4)
	Primary care	11 (3)
	Diabetes	11 (3)
	Urology	10 (3)
	Neurology	10 (3)
	Infectious Disease	8 (2)
Dentistry	5 (1)	
Other ^B	60 (15)	
Setting (n=388)	Hospital	219 (56)
	General Practice	55 (14)
	Mixed	61 (16)
	Community	34 (9)
	Other ^C	19 (5)
Intervention Type (n=388)	Pharmaceutical Intervention	111 (29)
	Complex Intervention	65 (17)
	Therapy	54 (14)
	Surgery	46 (12)
	Other ^D	112 (29)
Control Type (n=388)	Placebo	87 (22)
	Active	301 (78)
Patient Blinded (n=384)	Yes	100 (26)
	No	284 (74)
Centres outside the UK? (n=388)	Yes	33 (9)
	No	355 (91)
Geographical Spread (n=388)	Multiple Regions	317 (82)
	Regional	71 (18)
Some form of pilot? ^E (n=388)	Yes	194 (50)
	No	194 (50)

^A 2 or 3 parallel RCTs, cohort multiple RCT, patient preference/Zelen's

^B Alcohol abuse, allergy, chronic fatigue, cystic fibrosis, gerontology, hepatology, intensive care, minor surgery, multiple sclerosis, obesity/weight loss, nephrology, neurosurgery, nutrition, ophthalmology, otorhinolaryngology, paediatric (general, anaesthesiology, dermatology, nephrology, obesity/weight loss), physical exercise, rehabilitation, reproductive health resuscitation, septic shock, sleep disorders, speech therapy, vascular

^C Bowel Cancer Screening Programme, Exercise Schemes, Football Clubs, HIV Clinics, Intellectual Disability Services, Leisure Centres, Mobile Dental Clinics, Online, Physical Therapy Classes, Prison, Public School, Sexual Health Clinics, Specialist Care Centres, Stop Smoking Services, University Clinics

^D Advice and Information, Consultation, Diagnostic Information, Drug vs Surgery, Equipment, Health Professional, Patient Pathway, Technique

^E Any mention of pilot work or feasibility study recorded.

Table 2: Recruitment and sample size characteristics of the trials included in the review

Characteristic (n = 388)		n (%)	Mean (SD)	Median (IQR)	Range
Number of Centres	1	26 (7)	29 (34)	17 (7 - 37)	1 - 274
	2-5	60 (15)			
	6-10	48 (12)			
	11-20	69 (18)			
	21-50	112 (29)			
	51-100	48 (12)			
	> 100	16 (4)			
	Missing	9 (2)			
Original Target Recruitment	≤ 200	49 (13)	1,097 (3,080)	500 (300 - 900)	50 - 46,000
	201-400	101 (26)			
	401-600	86 (22)			
	601-800	41 (11)			
	> 800	109 (28)			
	Missing	2 (1)			
Final Target Recruitment	≤ 200	53 (14)	1,041 (3,074)	480 (270 - 802)	44 - 46,000
	201-400	112 (29)			
	401-600	84 (22)			
	601-800	42 (11)			
	> 800	97 (25)			
Final Total Recruitment	≤ 200	72 (19)	991 (3,025)	452 (236 - 800)	2 - 47,062
	201-400	99 (26)			
	401-600	82 (21)			
	601-800	39 (10)			
	> 800	96 (25)			
Final Recruitment Target Achieved	Yes	245 (63)			
	No, but with ≥ 80% of target	86 (22)			
	No, < 80% of target	57 (15)			
Timing of Primary Outcome Follow-Up (months post-randomisation)	≤ 1 month	42 (11)	12 (13)	10 (3 - 12)	0 - 120
	1 < months ≤ 6	129 (33)			
	6 < months ≤ 18	131 (34)			
	> 18 months	63 (16)			
	Missing	23 (6)			
Timing of Final Follow-Up (months post-randomisation)	≤ 1 month	20 (5)	16 (19)	12 (6 - 18)	0.066 - 144
	1 < months ≤ 6	87 (22)			
	6 < months ≤ 18	181 (47)			
	> 18 months	88 (23)			
	Missing	12 (3)			

Table 3: Data completeness in relation to CONSORT guidelines and recruitment information

Trial Characteristic (N=388)	n (%)
Number Screened	327 (84)
Number eligible	309 (80)
Number refused/declined consent	282 (73)
Total recruitment	388 (100)
Number included in primary analysis (retention)	388 (100)
Number of centres	379 (98)
Maximum recruitment length	369 (95)
Centre-specific recruitment length	97 (25)
Recruitment rate can be calculated	365 (94)

CONSORT, Consolidated Standards of Reporting Trials

For peer review only

Table 4: Overall recruitment and retention rates

	Median	IQR	Range
Eligible participants consented and randomised (n=309)	72%	50-88%	4 - 100%
Recruited per centre per month (n=365)	0.95	0.42-2.60	0.01 - 57.75
Randomised participants retained and assessed in primary outcome (n=388)	88%	80-97%	0 - 100%

For peer review only

Table 5: Association between recruitment rate (number of participants/centre/month) and trial characteristics

Characteristic (n=365)		n	Median	IQR	P-Value
Setting	Hospital	212	0.90	0.4 - 2.29	0.008 ^{A,B}
	General Practice	51	0.71	0.32 - 1.18	
	Mixed	56	1.01	0.47 - 2.64	
	Community	29	2.44	0.62 - 6.41	
	Other	17	1.89	0.76 - 11.7	
Arms	2	278	1.10	0.41 - 2.76	0.941 ^C
	3	55	0.85	0.45 - 2.1	
	4	22	1.04	0.57 - 1.91	
	>4	10	0.85	0.42 - 8.85	
Control Type	Placebo	85	0.84	0.38 - 1.93	0.143 ^D
	Active	280	1.03	0.43 - 3.22	
Original Target Recruitment	≤ 200	41	1.18	0.47 - 2.65	0.01 ^C
	201-400	93	0.78	0.36 - 2.01	
	401-600	84	0.84	0.43 - 1.96	
	601-800	40	1.13	0.46 - 2.88	
	> 800	105	1.49	0.55 - 4.72	
Final Target Recruitment	≤ 200	45	0.89	0.27 - 2.55	<0.001 ^C
	201-400	103	0.76	0.34 - 1.96	
	401-600	83	0.86	0.44 - 2.26	
	601-800	41	1.17	0.57 - 4.23	
	> 800	93	1.66	0.58 - 5.17	
Total Recruitment	≤ 200	63	0.50	0.17 - 1.6	<0.001 ^C
	201-400	90	0.78	0.37 - 2.07	
	401-600	81	1.15	0.49 - 2.41	
	601-800	39	1.03	0.57 - 3.85	
	> 800	92	1.96	0.68 - 6.23	
Timing of Final Follow-Up	≤ 1 month	19	1.29	0.42 - 2.26	0.166 ^C
	1 < months ≤ 6	82	1.14	0.38 - 4.14	
	6 < months ≤ 18	170	0.98	0.46 - 2.33	
	> 18 months	85	0.71	0.36 - 2.02	

^A The category 'other' was not included in Kruskal-Wallis test

^B P-Values are reported from a Kruskal-Wallis test

^C P-Values are reported from a Jonckheere-Terpstra test

^D P-Values are reported from a Mann-Whitney U test

Table 6: Association between the trial retention rate (% of randomised participants with valid primary outcome data for analysis) and trial characteristics

Characteristic (n=388)		n	Median	IQR	P-Value
Setting	Hospital	219	91.5	82.2 - 97.8	<0.001 ^{A,B}
	General Practice	55	84.0	76.6 - 91.3	
	Mixed	61	87.3	79.7 - 97.3	
	Community	34	84.9	75.4 - 90.8	
	Other	19	84.2	74.9 - 96.5	
Arms	2	290	89.9	81 - 97.4	<0.001 ^C
	3	61	84.4	72.4 - 93.6	
	4	24	83.2	79.6 - 88.2	
	>4	13	80.2	73.4 - 96.4	
Control Type	Placebo	87	89.8	79.1 - 97.3	0.614 ^D
	Active	301	87.8	80.3 - 96.4	
Final Target Recruitment	≤ 200	53	88.6	79.6 - 96.4	0.003 ^C
	201-400	112	86.1	77.1 - 94.1	
	401-600	84	86.8	78.9 - 95.7	
	601-800	42	84.4	80.4 - 90.9	
	> 800	97	96.3	85.3 - 99.1	
Total Recruitment	≤ 200	72	87.9	74.5 - 96.2	<0.001 ^C
	201-400	99	87.3	79.3 - 94.9	
	401-600	82	86.4	80.6 - 94.1	
	601-800	39	86.2	82.2 - 91.4	
	> 800	96	95.8	82.4 - 99	
Timing of Final Follow-Up	≤ 1 month	20	92.2	78.7 - 99	0.895 ^C
	1 < months ≤ 6	87	88.5	79.8 - 96.7	
	6 < months ≤ 18	181	88.2	79.5 - 96.4	
	> 18 months	88	87.8	80 - 95.5	

^A The category 'other' was not included in Kruskal-Wallis test

^B P-Values are reported from a Kruskal-Wallis test

^C P-Values are reported from a Jonckheere-Terpstra test

^D P-Values are reported from a Mann-Whitney U test

Table 7: Comparison of the current review with three previous reviews in terms of successful recruitment to target sample size and extensions to recruitment

Review	McDonald <i>et al.</i>(7)	Sully <i>et al.</i>(5)	Walters <i>et al.</i>(8)	This study	This study
Recruitment period	1994-2002	2002-2008	2004-2016	2017-2020	1997-2020
Number of trials in the study	N = 122	N = 73	N = 151	N = 174	N = 388
Recruited 100% of original target	38 of 122 (31%)	40 of 73 (55%)	61 of 151 (40%)	107 of 174 (61%)	207 of 388 (53%)
Original target was revised	42 of 122 (34%)	14 of 73 (19%)	52 of 151 (34%)	54 of 174 (31%)	118 of 388 (30%)
Original target revised upward	6 of 42 (14%)	5 of 14 (36%)	11 of 52 (21%)	23 of 54 (43%)	39 of 118 (33%)
Original target revised downward	36 of 42 (86%)	9 of 14 (64%)	41 of 52 (79%)	31 of 54 (57%)	79 of 118 (67%)
Recruited 80% of original target	67 of 122 (55%)	57 of 73 (78%)	95 of 151 (63%)	139 of 174 (80%)	288 of 388 (74%)
Recruited 100% of revised target	19 of 42 (45%)	10 of 14 (71%)	28 of 52 (54%)	35 of 54 (65%)	80 of 118 (68%)
Recruited 80% of revised target	34 of 42 (80%)	13 of 14 (93%)	48 of 52 (92%)	48 of 54 (89%)	107 of 118 (91%)
Extended their recruitment	65 of 122 (54%)	33 of 73 (45%)	49 of 151 (32%)	65 of 174 (37%)	128 of 388 (33%)




Figure 1: Flow diagram of search and selection process of individually RCTs from the five NIHR journals between 1 January 1997 and 31 December 2020




Figure 2: Boxplots of recruitment rates by clinical area

228x152mm (300 x 300 DPI)




Figure 3: Number of trials and proportion of trials recruiting 100% and ≥80% of the final sample size target from 1997 to 2020

228x152mm (300 x 300 DPI)



PRISMA 2020 Checklist

36/bmjopen-2021-059230 on 14 February 2022. Downloaded from <http://bmjopen.bmj.com/> on 05 April 2022. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page 1 (title indicates this this a review)
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Pages 2 & 3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Pages 5 & 6
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 6
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Pages 6 & 7
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Pages 6 & 7
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Page 7
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Page 8
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Page 8
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Pages 8 & 9
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Page 8 & 9
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	NA
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	The primary outcome (recruitment rate) is described on pages 8 & 9.
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	NA
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Analysis methods are described



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
			on pages 8 & 9.
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Analysis methods are described on pages 8 & 9.
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Analysis methods are described on pages 8 & 9.
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	NA
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	NA
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	NA
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	NA
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	NA
Study characteristics	17	Cite each included study and present its characteristics.	NA
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	NA
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	NA
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	NA
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Results are described on pages 10 to 12; and in Tables 1 to 7
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	NA



PRISMA 2020 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section and Topic	Item #	Checklist item	Location where item is reported
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	NA
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	NA
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	NA
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Pages 13 & 14
	23b	Discuss any limitations of the evidence included in the review.	Pages 13 & 14
	23c	Discuss any limitations of the review processes used.	Page 14
	23d	Discuss implications of the results for practice, policy, and future research.	Pages 13 & 14
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	NA
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	NA
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	NA
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 14
Competing interests	26	Declare any competing interests of review authors.	Page 15
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Page 15

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>

36/bmjopen-2021-059230 on 14 February 2022. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.

BMJ Open

Recruitment, consent and retention of participants in randomised controlled trials: a review of trials published in the National Institute for Health Research (NIHR) Journals Library (1997 – 2020)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059230.R1
Article Type:	Original research
Date Submitted by the Author:	12-Jan-2022
Complete List of Authors:	Jacques, Richard; The University of Sheffield, School of Health and Related Research Ahmed, Rashida; The University of Sheffield, School of Health and Related Research Harper, James; The University of Sheffield, School of Health and Related Research Ranjan, Adya; The University of Sheffield, School of Health and Related Research Saeed, Isra; The University of Sheffield, School of Health and Related Research Simpson, Rebecca; The University of Sheffield, School of Health and Related Research Walters, Stephen; The University of Sheffield, School of Health and Related Research
Primary Subject Heading:	Research methods
Secondary Subject Heading:	Research methods, Public health
Keywords:	STATISTICS & RESEARCH METHODS, AUDIT, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Recruitment, consent and retention of participants in randomised controlled trials: a
4 review of trials published in the National Institute for Health Research (NIHR)
5 Journals Library (1997 – 2020)
6
7
8
9
10

11 Richard M Jacques, Rashida Ahmed, James Harper, Adya Ranjan, Isra Saeed,
12 Rebecca M Simpson, Stephen J Walters
13
14
15

16
17
18 School of Health and Related Research, University of Sheffield, Sheffield, UK
19
20
21

22
23 Corresponding author:
24

25 Dr Richard Jacques
26

27 Email: r.jacques@sheffield.ac.uk
28
29
30
31

32 School of Health and Related Research
33

34 University of Sheffield
35

36 30 Regent Street
37
38

39 Sheffield
40
41

42 S1 4DA
43
44
45
46
47

48 **Word count:** 3766
49

50 **Number of figures and tables:** 3 figures, 7 tables
51

52 **Keywords:** randomised controlled trials; recruitment; consent; retention
53
54
55
56
57
58
59
60

Abstract

Objectives

To review the consent, recruitment and retention rates for randomised controlled trials (RCTs) funded by the United Kingdom's National Institute for Health Research (NIHR) and published in the online NIHR Journals Library between January 1997 and December 2020.

Design

Comprehensive review.

Setting

RCTs funded by the NIHR and published in the NIHR Journals Library.

Data extraction

Information relating to the trial characteristics, sample size, recruitment and retention.

Primary and secondary outcome measures

The primary outcome was the recruitment rate (number of participants recruited per centre per month). Secondary outcomes were the target sample size and whether it was achieved; consent rates (percentage of eligible participants who consented and were randomised) and retention rates (percentage of randomised participants retained and assessed with valid primary outcome data).

Results

This review identified 388 individual RCTs from 379 reports in the NIHR Journals Library. The final recruitment target sample size was achieved in 63% (245/388) of the RCTs. The original recruitment target was revised in 30% (118/388) of trials (downwards in 67% (79/118)). The median recruitment rate (participants per centre per month) was found to be 0.95 (IQR: 0.42 to 2.60); the median consent rate was 72% (IQR: 50% to 88%) and the median retention rate was estimated at 88% (IQR: 80% to 97%).

Conclusions

There is considerable variation in the consent, recruitment and retention rates in publicly funded RCTs. Although the majority of (six out of ten) trials in this review achieved their final target sample; three out of ten trials revised their original target sample size (downwards in seven out of ten trials). Investigators should bear this in mind at the planning stage of their study and not be overly optimistic about their recruitment projections.

For peer review only

Strengths and limitations of this study

- This is the largest comprehensive review of recruitment, consent and retention in trials to date reporting rates for 388 single and multicentre trials published in the National Institute for Health Research (NIHR) Journals Library between January 1997 and December 2020.
- As the NIHR Journals Library intends to publish all research from Efficacy and Mechanism Evaluation (EME), Health Services and Delivery Research (HS&DR), Health Technology Assessment (HTA), Programme Grants for Applied Research (PGfAR) and Public Health Research (PHR) funded projects, this study has less chance of publication bias compared to a review of other journals where publishing is more selective.
- For some trials crude recruitment rates, assuming all centres were recruiting for the same time period, were calculated, these estimates may be an underestimation of the true recruitment rate.
- The review is restricted to publicly funded trials published in the NIHR Journals Library, which may limit the generalisability of the findings.

Introduction

Randomised Controlled Trials (RCTs) are the 'gold-standard' research design for evaluating the effectiveness of interventions in health, education and policy.(1) Conducting an RCT requires major financial investment and substantial amounts of public funding is spent in this area each year. In 2019/2020 the National Institute for Health Research (NIHR) in England awarded over £250 million of funding to 310 research projects with a substantial proportion of this invested in RCTs.(2)

There are many practical challenges associated with conducting clinical trials. The leading reason for premature discontinuation of RCTs is poor recruitment of participants (3,4) with accrual often taking longer or being more difficult than expected. Poor recruitment can have a number of consequences including the study being underpowered if the target sample size is not met and increased costs if an extension is required.(5) Furthermore discontinued RCTs are less likely to be published in medical journals (3) which has ethical implications around research waste.(6)

There have been a number of previous studies in the United Kingdom (UK) investigating recruitment and retention in publicly funded RCTs. The earliest review, a cohort of trials funded by the Medical Research Council (MRC) and NIHR Health Technology Assessment (HTA) between 1994 and 2002, reported that 31% (38/122) of the trials successfully recruited to their original recruitment target, with 54% (65/122) of trials awarded a grant extension.(7) There is evidence of a marginal improvement in these figures over time, with results from a cohort of 151 RCTs funded by the NIHR HTA programme between 2004 and 2016 finding that 40% (61/151) of trials successfully recruited to their original sample size, and 32% (49/151) of trials extended their recruitment.(8) In the same study the median recruitment rate was found to be 0.92 (IQR: 0.43-2.79) participants per centre per month.

Following the publication of the review by Walters *et al.*(8) in 2017 there have been several Cochrane systematic reviews looking at strategies for improving recruitment (9) and retention (10) of participants in RCTs. Two strategies for improving

1
2
3 recruitment were identified with high-certainty evidence: using open trials rather than
4 blinded, placebo controlled trials, and telephone reminders to people who did not
5 respond to postal invitations. There has also been a systematic review of statistical
6 models for predicting recruitment at the design stage of a clinical trial (11) but a
7 survey of statisticians in UK and European clinical trial networks found that 90%
8 (62/69) did not use statistical models for recruitment prediction.(12) In 2014 a trials
9 methodology research priority setting exercise was conducted using a Delphi survey
10 of directors of UK Clinical Research Collaboration registered Clinical Trials Units.(13)
11 Two of the three highest priority areas were 'Research methods to boost recruitment
12 in trials' and 'Methods to minimise attrition'.
13
14
15
16
17
18
19
20
21

22 The Consolidated Standards of Reporting Trials (CONSORT) statement was first
23 published in 1996 (14), and revised in 2001 (15) and 2010.(16) It is a checklist of
24 standards for reporting how a trial was designed, analysed and interpreted, and it
25 has been endorsed both by prominent general medical journals and many specialist
26 medical journals.(17) However, reporting guidelines such as CONSORT are not
27 adopted and adhered to as much as they should be (18) with the previous review of
28 recruitment and retention in RCTs by Walters *et al.*(8) finding that 63% (95/151) of
29 trials demonstrated complete compliance with CONSORT statement and reported
30 each of the number: screened, eligible, declined consent, recruited and assessed for
31 their primary outcome.
32
33
34
35
36
37
38
39
40

41 This review aims to update previous research on how well recruitment and retention
42 figures are reported, and the rates of recruitment and retention in trials published in
43 the NIHR HTA journal between January 2004 and April 2016.(8) In this study, we
44 update and extend this review to look at trials published in the NIHR Journals library
45 from January 1997 to December 2020.
46
47
48
49
50

51 **Methods**

52 **Trial Identification**

53 Reports of individually RCTs published in the NIHR Journals Library from January
54 1997 to December 2020 were reviewed. Established in 2006, the NIHR is now the
55 largest funder of health and social research in England.(2) The NIHR Journals
56
57
58
59
60

1
2
3 Library publishes five peer reviewed journals reporting the results from a range of
4 health research areas: Efficacy and Mechanism Evaluation (EME), Health Services
5 and Delivery Research (HS&DR), Health Technology Assessment (HTA),
6
7 Programme Grants for Applied Research (PGfAR) and Public Health Research
8 (PHR) (<https://www.journalslibrary.nihr.ac.uk/journals/>). The first volume of the HTA
9 journal was published in 1997 whereas the other four journals are more recent with
10 the first volumes of the HS&DR, PGfAR and PHR journals published in 2013 and the
11 first volume of the EME journal published in 2014. Trial reports published in the
12 NIHR Journals Library were chosen as they provide a detailed description of the
13 research methods and study results including recruitment and retention information.
14
15
16
17
18
19
20
21

22 The reports for review were obtained from the NIHR Journals Library website
23 (<https://www.journalslibrary.nihr.ac.uk/> - last accessed 10 November 2021) along
24 with any published trial paper, protocol paper or trial protocol. The published
25 International Standardised Randomised Controlled Trial Number (ISRCTN) was
26 used where available to check the ISRCTN register of clinical trials for additional
27 information (<https://www.isrctn.com/>). The titles and abstracts of all reports published
28 in the five NIHR journals from 1st January 1997 to 31st December 2020 were
29 checked for relevance.
30
31
32
33
34
35
36
37

38 **Inclusion/Exclusion Criteria**

39 To ensure consistency the eligibility criteria used by Walters *et al.*(8) was adopted.
40 Reports included in the review were of single or multicentre RCTs that were either
41 fully or partially randomised and where recruitment to the trial had finished. Reports
42 of trials that terminated early, either prior to completion of recruitment or following
43 recruitment but prior to completion of follow-up were retained. Reports of two or
44 more parallel RCTs were included as were nested parallel trials as part of another
45 RCT. Some reports in the PGfAR journal included multiple independent RCTs and
46 each of these trials were included separately. Reports of non-RCTs, cluster RCTs,
47 adaptive designs, influenza vaccination trials, follow-on studies and ongoing RCTs
48 that had not completed recruitment were excluded. Reports of external
49 pilot/feasibility studies were excluded as they do not contribute outcome data to the
50 main trial and are instead often used to estimate parameters such as the number of
51
52
53
54
55
56
57
58
59
60

1
2
3 eligible participants, willingness of participants to be randomised and follow-up rates
4 needed for the design of the main study.(19) Reports of internal pilot trials that either
5 went on to contribute outcome data to a full trial or were terminated prior to the full
6 trial because of recruitment issues were included in the review.
7
8
9

10 11 12 **Data Extraction**

13
14 After the NIHR reports had been selected for inclusion, information was extracted
15 using a standardised data extraction form. For each of the included trials the
16 following information was extracted.
17
18
19

- 20
21 ● Trial characteristics, including the trial design, clinical area, type of
22 intervention, type of control, number of arms, use of blinding of trial
23 participant, geographical region, number of centres, any support provided by
24 a Clinical Trials Unit (CTU) and whether there was any description of pilot or
25 feasibility work done prior to the start of the trial.
26
27
28
29
- 30
31 ● Sample size, recruitment and retention information, including the target and
32 actual sample size, the overall and centre-specific recruitment period and
33 CONSORT information on the numbers screened, consented, randomised
34 and analysed for the primary outcome.(16)
35
36
37
38
39

40
41 The selection of RCTs and data extraction was conducted by a team of reviewers
42 (RMJ, RA, JH, AR and IS). Three reviewers (RMJ, RMS and SJW) conducted quality
43 assurance checks on 30% of the included trials after the data extraction was
44 completed, and disagreements were discussed to achieve consensus.
45
46
47
48

49 **Analysis**

50
51 The primary outcome for the review was the recruitment rate for each trial. This was
52 defined as the number of participants recruited and randomised per centre per
53 month. Where explicit dates were reported the recruitment rate was calculated as the
54 time between the date of recruitment start and the date of recruitment completion. In
55 cases where only the months of recruitment were reported the recruitment period
56
57
58
59
60

1
2
3 was estimated as the time between the 1st of the month and the end of the final
4 month. If the date of the first participant recruited was reported instead of the start
5 date of recruitment then the start of recruitment was taken as the 1st of the month of
6 the first participant recruited. When the start of recruitment was not reported the start
7 of screening was used to calculate the recruitment period. The recruitment period
8 was estimated by subtracting the length of the follow-up period from the length of the
9 study period when explicit information on the start and end of recruitment was not
10 reported.
11
12
13
14
15
16
17

18
19 The recruitment rate was calculated in two different ways. The overall recruitment
20 rate was calculated as the total number of participants recruited divided by the
21 maximum number of recruiting sites, then divided by the total number of months that
22 the trial recruited for. This overall recruitment rate is likely to be an underestimate for
23 multicentre trials because each trial site is unlikely to open for recruitment at the
24 same time and will not recruit for the entire recruitment period. To allow for the
25 difference in start-up times and recruitment periods between sites, where available,
26 the site-specific recruitment periods were extracted. These were averaged over the
27 number of sites to give an average site-specific recruitment period. The average
28 recruitment rate was calculated as the total number of participants recruited divided
29 by the maximum number of sites, then divided by the average number of months that
30 the trial recruited for.
31
32
33
34
35
36
37
38
39
40

41 The secondary outcomes for the review were the target sample size and whether it
42 was achieved, the consent rate and the retention rate. The consent rate was
43 calculated as the percentage of eligible participants that consented and were
44 randomised (i.e. the total number of participants recruited and randomised divided by
45 the number of eligible participants). The retention rate was calculated as the
46 percentage of randomised participants that were assessed for the primary outcome
47 and included in the analysis of the primary outcome (i.e. the number of participants
48 included in the analysis of the primary outcome divided by the number of participants
49 recruited and randomised).
50
51
52
53
54
55
56
57

58 Recruitment rates were summarised using the median and interquartile range (IQR)
59 due to the skewed distribution of the data.(20) The median and IQR were also used
60

1
2
3 to summarise the secondary outcomes of the consent and retention rates.
4
5 Comparisons of recruitment and retention rates were made between different trial
6 characteristics using appropriate non-parametric tests; Mann-Whitney U test (for
7 characteristics with two levels), Kruskal-Wallis test (three or more nominal levels)
8 and Jonckheere-Terpstra test (three or more ordered levels). Analysis was
9 conducted on a complete case basis so where the characteristics information,
10 recruitment rate or retention rate were missing these were excluded. All statistical
11 analysis was conducted in R version 4.1.0 (21), figures were produced using the
12 package ggplot2 (22), and the Jonckheere-Terpstra test conducted using the
13 package clinfun.(23)
14
15
16
17
18
19
20
21

22 **Patients and public involvement**

23
24
25 Patients and/or the public were not involved in the design, conduct, reporting or
26 dissemination plans of this research.
27
28
29

30 **Results**

31
32
33 Between 1st January 1997 and 31st December 2020, 1899 reports were published in
34 the five NIHR journals. Following screening, 1299 of these were excluded as reports
35 of non-RCTs. The search identified 600 reports of RCTs of which 221 were excluded
36 after applying the exclusion criteria (101 cluster RCTs; 95 pilot/feasibility RCTs; 14
37 follow-on studies; 6 adaptive designs; 3 influenza vaccination trials; and 2 ongoing
38 trials). Eight NIHR reports described the results of multiple independent trials (7
39 reports described 2 RCTs and 1 described 3 RCTs), therefore in total, 388 individual
40 RCTs from 379 reports were included in the review and analysed as shown in Figure
41 1. This includes 151 RCTs from the review by Walters *et al.*(8).
42
43
44
45
46
47
48
49

50 **Trial Characteristics**

51
52
53 The characteristics of the 388 trials included in the review are summarised in Table
54 1. The most common design was a two arm parallel group, multicentre RCT. The
55 most frequently studied clinical areas were mental health, including psychiatry and
56 psychology (19% (73/388) of trials) and musculoskeletal conditions, including
57 orthopaedics, rheumatology and back pain (11% (44/388) of trials). The majority of
58
59
60

1
2
3 trials were set in hospitals (56% (219/388)), took place in the UK (91% (355/388))
4 and across multiple geographic regions (82% (317/388)). Trials of pharmaceutical
5 interventions (29% (111/388)) were more common than other interventions and 78%
6 (301/388) of trials used an active control. Half of all trial reports (194/388) reported or
7 mentioned work from a pilot or feasibility study.
8
9
10
11
12

13 The recruitment and sample size characteristics of the RCTs included in the review
14 are summarised in Table 2. The majority of trials (354/388) were multicentre with a
15 median of 17 centres (IQR: 7 to 37). The final recruitment target (sample size)
16 ranged from 44 participants to 46,000 participants and the final number recruited
17 ranged from 2 participants to 47,062. The RCT with the highest final recruitment
18 target and highest number recruited was an obstetrics trial investigating
19 computerised interpretation of fetal heart rate during labour.(24) There were four
20 trials that recruited less than ten participants, two were discontinued at the end of an
21 internal pilot phase due to low recruitment (25,26) and the remaining two had no pilot
22 phase.(27,28) Overall, 63% (245/388) of trials recruited to their final recruitment
23 target but 32% (79/245) of these trials required an extension to their recruitment
24 period to meet the target. A further 22% (86/388) of trials recruited to within 80% of
25 their final recruitment target with 36% (31/86) of these trials having an extension to
26 their recruitment period. The original recruitment target was revised in 30%
27 (118/388) of trials (downwards in 67% (79/118)). For the majority of trials the primary
28 outcome was collected at between 1 and 18 months post-randomisation.
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **CONSORT and Recruitment Data**

44
45 Summaries of the data completeness in relation to the CONSORT statement,
46 recruitment and retention are presented in Table 3. Of the 388 RCTs identified, 68%
47 (265/388) fully complied with the CONSORT statement and reported the number of
48 participants screened, eligible, declined consent, recruited and assessed for the
49 primary outcome. The total number of participants recruited and randomised, and the
50 number included in the analysis of the primary outcome, used to measure retention,
51 was available for all 388 trials. Regarding the information required to calculate the
52 recruitment rate, 98% (379/388) of trials reported the number of centres, 95%
53 (369/388) reported the maximum length of the recruitment period, and 25% (97/388)
54
55
56
57
58
59
60

1
2
3 reported the centre-specific recruitment information used to calculate an average
4 recruitment period per centre. There was enough information reported to calculate
5 the overall recruitment rate for 94% (365/388) of trials in this review.
6
7
8
9

10 **Recruitment, Consent and Retention Rates**

11
12
13 From the 365 trials with sufficient information to calculate the recruitment rate, the
14 median was found to be 0.95 participants recruited per centre per month. The
15 highest recruitment rate (57.75 participants per centre per month) was in a trial
16 comparing medical to surgical termination of pregnancy with a target sample size of
17 2,232 women (29) and the lowest (0.01 participants per centre per month) was in a
18 trial treatment for transverse myelitis.(27) The 80th and 90th percentiles were found to
19 be 3.70 and 9.47 participants recruited per centre per month, respectively. From the
20 22 single centre trials with sufficient information, the median recruitment rate was
21 found to be 14.12 (IQR: 4.29-26.59, range: 1.58-57.75) participants per centre per
22 month compared with a median of 0.86 (IQR: 0.40-2.17, range: 0.01-51.14)
23 participant per centre per month in the 343 multi-centre trials. Table 4 shows some
24 statistical evidence of a difference in recruitment rates between the five NIHR
25 journals (P=0.010) with the PHR journal having the highest median recruitment rate
26 (7.62, IQR: 1.79-17.06) and the HTA journal having the lowest (0.85, IQR: 0.39-
27 2.49). However, there are only six trials from the PHR journal included in this review
28 and three of these trials (30–32) have a recruitment rate of ten participants per
29 centre per month or greater. Figure 2 shows the distribution of recruitment rates by
30 clinical area. The highest median recruitment rate was for dentistry (1.95 participants
31 recruited per centre per month) but this was only from five trials. The largest
32 recruitment rates were found to be from four obstetrics and gynaecology trials
33 (24,29,33,34), a mental health trial (35), and three trials from other clinical areas
34 (36–38).
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 The median consent rate (percentage of eligible participants consented and
53 randomised) was found to be 72% (IQR: 50-88%). Table 4 shows some variability in
54 consent rates between the journals with the HS&DR journal having the largest
55 median rate (81%, IQR: 60-97%) and the PHR journal the lowest (57%, IQR: 40-
56 68%). However, there is not an overall statistically significant difference in consent
57
58
59
60

1
2
3 rates between the five NIHR journals ($P=0.225$). The median retention rate (percent
4 of randomised participants retained and assessed in the analysis of the primary
5 outcome) was found to be 88% (IQR: 80-97%). There were four trials (25,26,28,39)
6 with a retention rate of 0%, these trials were all stopped early due to problems with
7 recruitment and the planned statistical analysis for the primary outcome was not
8 performed. Retention rates do not differ greatly between the five NIHR journals
9 ($P=0.118$) (Table 4).
10
11
12
13
14
15
16

17 The trial recruitment and retention rates are summarised by trial characteristics in
18 Tables 5 and 6 respectively. There is some statistical evidence of an association
19 between the setting of the trial, final recruitment target and the total number of
20 participants recruited but the median rates show no clear patterns to these
21 associations.
22
23
24
25
26

27 The results of the current review, in terms of successful recruitment to target sample
28 size, have been compared with three previous reviews (5,7,8) in Table 7. As this
29 review updates the findings of Walters *et al.*(8) and due to there being some overlap
30 with the trials included in Sully *et al.*(5); a column has been included for the non-
31 overlapping time interval (2017-2020) in addition to the full time interval (1997-2020).
32 Table 7 shows that 61% (107/174) of trials in the period 2017-2020 recruited 100%
33 of the original target sample size which is higher than the previous periods/reviews.
34 The target sample size was revised in 31% (54/174) of trials; and the revision was
35 downwards for 57% (31/54) of trials. An extension, to the trial timelines, was reported
36 in 37% (65/174) of trials and this was higher than the review by Walters *et al.*(8)
37 (32% (49/151)) but lower than the reviews by McDonald *et al.*(7) (54% (65/122)) and
38 Sully *et al.*(5) (45% (33/73)).
39
40
41
42
43
44
45
46
47
48
49

50 Figure 3 shows the percentage of trials recruiting 100% of the final target and 80% or
51 more of the final target by publication year. There is no clear trend in the percentage
52 of trials recruiting 100% of the final target for the earlier years (1999-2006) but there
53 is evidence of an upward trend for the years 2007 to 2020.
54
55
56
57
58
59
60

Discussion and Conclusions

This study has systematically conducted a review of the recruitment and retention data from a cohort of 388 trials published in the NIHR Journals Library between 1997 and 2020. This review found that the final target sample size was achieved in 63% (245/388) of RCTs; the median recruitment rate was 0.95 (IQR: 0.42-2.60) participants per centre per month; the median consent rate was 72% (IQR: 50-88%); and the median retention rate was 88% (IQR: 80-97%).

This review found that 53% (207/388) of publicly funded RCTs achieved their original target sample size. Restricting the time period to 2017-2020 the figure is 61% (107/174), this is higher than the previous figures of 55% and 40% found in the reviews by Sully *et al.*(5) and Walters *et al.*(8) This is also reflected in the percentage of trials recruiting to 100% of their final target where there is some evidence of an upward trend for the years 2007 to 2020. However, there is some evidence of a difference in recruitment rates between the five NIHR journals and therefore any improvement may be due to the inclusion of trials from the journals (EME, PGfAR, HS&DR and PHR) that were not included in the review by Walters *et al.*(8) There is still cause for some concern with 30% (118/388) of trials revising their original recruitment target with the majority (67% (79/118) revising the target downwards, and a third (128/338) of trials having an extension to their recruitment period. These findings remain consistent with the concerns expressed by clinical trials unit directors.(13)

The median consent and retention rate are consistent with the result of Walters *et al.*(8) The retention figure may be an overestimate as it will be affected by trials using time to event outcomes, where missing outcomes are censored at the time of loss to follow-up but included in analyses using survival models. The target sample size for any trial should allow for participant withdrawals and loss to follow-up (40) with the expected withdrawal proportion obtained from reports of studies conducted in the same clinical area.(20) However, if no such information is available then a pragmatic

1
2
3 approach would be to use the median retention rate from this review (88%) and
4 assume an expected withdrawal proportion of at least 10%.
5
6
7
8
9

10 This study has the following limitations. First, the review was restricted to publicly
11 funded trials published in the NIHR Journals Library, which may limit the
12 generalisability of the findings. It is possible that that problems with recruitment and
13 retention of participants in NIHR funded trials will be less pronounced than in other
14 trials due to the rigorous appraisal of feasibility prior to funding and the ongoing
15 monitoring during the conduct of the trial. However, as the NIHR Journals Library
16 intends to publish all research from EME, HS&DR, HTA, PGfAR and PHR funded
17 projects, it has less chance of publication bias compared to a review of other journals
18 where publishing is more selective and information related to recruitment is
19 published in less detail. Second, the data extraction was conducted by several
20 independent reviewers and although reviewers conferred to try and ensure
21 consistency and quality assurance checks were completed on a sample of reports, it
22 is possible that errors have occurred. Third, the calculation of recruitment rates was
23 limited by the information reported. For some trials centre specific recruitment
24 information was not available meaning that crude recruitment rates, assuming all
25 centres were recruiting for the same time period, were calculated. In these cases the
26 calculated recruitment rate may be an underestimate of the true recruitment rate.
27
28
29
30
31
32
33
34
35
36
37
38

39 This review found considerable variation in the consent, recruitment and retention
40 rates in publicly funded RCTs. Although the majority of (six out of ten) trials in this
41 review achieved their final target sample; three out of ten trials published in NIHR
42 Journals Library revised their original target sample size (downwards in seven out of
43 ten trials). Investigators should bear this in mind at the planning stage of their study
44 and not be overly optimistic about their recruitment projections.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributions

RMJ and SJW contributed to the study concept and design. RMJ, RA, JH, AR and IS contributed to the selection of data and conducted the data extraction. RMJ conducted the data analysis and drafted the manuscript. RMJ, RMS and SJW contributed to the quality assurance check of the data. All authors critically revised the manuscript and approved the final manuscript.

Funding

SJW is an NIHR Senior Investigator supported by the NIHR (NF-SI-0617-10012) for this research project. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS or the UK Department of Health and Social Care. These organisations had no role in the study design; in the collection, analysis and interpretation of the data; in writing of the report; or in the decision to submit the paper for publication.

Competing Interests

RMJ, RMS and SJW received funding across various projects from the National Institute for Health Research (NIHR).

Patient consent for publication

Not required

Ethics approval

The information extracted in this review is based on trials published in the NIHR Journals Library where ethics approvals were obtained by the original trial teams. This review does not involve recruiting new participants or analysing individual participant data, and the original participants cannot be identified from this review.

Data availability statement

The information extracted in this review is based on published trials in the NIHR Journals Library. The data extracted is available upon reasonable request from the corresponding author at r.jacques@sheffield.ac.uk

For peer review only

References

1. Torgerson DJ, Torgerson CJ. *Designing Randomised Trials in Health, Education and the Social Sciences: An Introduction*. Basingstoke: PALGRAVE MACMILLAN; 2008.
2. National Institute for Health Research Annual Report 2019/20 [Internet]. [cited 2021 Oct 11]. Available from: https://www.nihr.ac.uk/documents/about-us/our-contribution-to-research/research-performance/NIHR_Annual_Report_19_20.pdf
3. Kasenda B, von Elm E, You J, Blümle A, Tomonaga Y, Saccilotto R, et al. Prevalence, Characteristics, and Publication of Discontinued Randomized Trials. *JAMA*. 2014 Mar 12;311(10):1045–52.
4. Amstutz A, Schandelmaier S, Frei R, Surina J, Agarwal A, Olu KK, et al. Discontinuation and non-publication of randomised clinical trials supported by the main public funding body in Switzerland: a retrospective cohort study. *BMJ Open*. 2017 Jul 1;7(7):e016216.
5. Sully BGO, Julious SA, Nicholl J. A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies. *Trials*. 2013 Jun 9;14(1):166.
6. Ioannidis JPA, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, et al. Increasing value and reducing waste in research design, conduct, and analysis. *The Lancet*. 2014 Jan 11;383(9912):166–75.
7. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. *Trials*. 2006 Apr 7;7(1):9.
8. Walters SJ, Henriques-Cadby IB dos A, Bortolami O, Flight L, Hind D, Jacques RM, et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. *BMJ Open*. 2017 Mar 1;7(3):e015276.
9. Treweek S, Pitkethly M, Cook J, Fraser C, Mitchell E, Sullivan F, et al. Strategies to improve recruitment to randomised trials. *Cochrane Database Syst Rev*. 2018 Feb 22;2018(2):MR000013.
10. Gillies K, Kearney A, Keenan C, Treweek S, Hudson J, Brueton VC, et al. Strategies to improve retention in randomised trials. *Cochrane Database Syst Rev*. 2021;(3).
11. Gkioni E, Rius R, Dodd S, Gamble C. A systematic review describes models for recruitment prediction at the design stage of a clinical trial. *J Clin Epidemiol*. 2019 Nov;115:141–9.

12. Gkioni E, Dodd S, Rius R, Gamble C. Statistical models to predict recruitment in clinical trials were rarely used by statisticians in UK and European networks. *J Clin Epidemiol*. 2020 Aug 1;124:58–68.
13. Tudur Smith C, Hickey H, Clarke M, Blazeby J, Williamson P. The trials methodological research agenda: results from a priority setting exercise. *Trials*. 2014 Jan 23;15(1):32.
14. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. *JAMA*. 1996 Aug 28;276(8):637–9.
15. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet Lond Engl*. 2001 Apr 14;357(9263):1191–4.
16. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010 Mar 24;340:c332.
17. Consort Transparent Reporting of Trials [Internet]. [cited 2021 Oct 14]. Available from: <http://www.consort-statement.org/>
18. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, et al. Reducing waste from incomplete or unusable reports of biomedical research. *The Lancet*. 2014 Jan 18;383(9913):267–76.
19. Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility study? A review of current practice and editorial policy. *BMC Med Res Methodol*. 2010 Jul 16;10(1):67.
20. Walters SJ, Campbell MJ, Machin D. *Medical Statistics: A Textbook for the Health Sciences*. 5th ed. Chichester: John Wiley & Sons, Ltd; 2021.
21. R Core Team. *R: A Language and Environment for Statistical Computing* [Internet]. Vienna, Austria; 2021. Available from: <https://www.R-project.org/>
22. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. New York: Springer-Verlag; 2016.
23. Seshan VE. *clinfun: Clinical Trial Design and Data Analysis Functions* [Internet]. 2018. Available from: <https://CRAN.R-project.org/package=clinfun>
24. Brocklehurst P, Field D, Greene K, Juszczak E, Kenyon S, Linsell L, et al. Computerised interpretation of the fetal heart rate during labour: a randomised controlled trial (INFANT). *Health Technol Assess*. 2018 Feb 13;22(9):1–186.
25. Davidson B, Gurusamy K, Corrigan N, Croft J, Ruddock S, Pullan A, et al. Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT. *Health Technol Assess*. 2020 May 1;24(21):1–38.

- 1
2
3 26. Williams NH, Jenkins A, Goulden N, Hoare Z, Hughes DA, Wood E, et al.
4 Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC):
5 a randomised controlled trial of adalimumab injection compared with placebo for
6 patients receiving physiotherapy treatment for sciatica. *Health Technol Assess.*
7 2017 Oct 24;21(60):1–180.
8
9
- 10 27. Absoud M, Brex P, Ciccarelli O, Diribe O, Giovannoni G, Hellier J, et al. A
11 multicentre randomised controlled TRial of IntraVENous immunoglobulin
12 compared with standard therapy for the treatment of transverse myelitis in
13 adults and children (STRIVE). *Health Technol Assess.* 2017 May 30;21(31):1–
14 50.
15
- 16 28. Strang J, Kelleher M, Mayet S, Day E, Hellier J, Byford S, et al. Extended-
17 release naltrexone versus standard oral naltrexone versus placebo for opioid
18 use disorder: the NEAT three-arm RCT. *Health Technol Assess.* 2019 Feb
19 1;23(3):1–72.
20
21
- 22 29. Robson SC, Kelly T, Howel D, Deverill M, Hewison J, Lie MLS, et al.
23 Randomised preference trial of medical versus surgical termination of
24 pregnancy less than 14 weeks' gestation (TOPS). *Health Technol Assess.* 2009
25 Nov 30;13(53):1–148.
26
27
- 28 30. Wyke S, Hunt K, Gray CM, Fenwick E, Bunn C, Donnan PT, et al. Football Fans
29 in Training (FFIT): a randomized controlled trial of a gender sensitised weight
30 loss and healthy living programme delivered to men aged 35-65 by Scottish
31 Premier League (SPL) football clubs. *Public Health Res.* 2015 Feb 11;3(2):1–
32 130.
33
34
- 35 31. Crombie IK, Irvine L, Williams B, Sniehotta FF, Petrie DJ, Jones C, et al. Text
36 message intervention to reduce frequency of binge drinking among
37 disadvantaged men: the TRAM RCT. *Public Health Res.* 2018 Jun 18;6(6):1–
38 156.
39
40
- 41 32. Daley A, Jolly K, Madigan C, Griffin R, Roalfe A, Lewis A, et al. A brief
42 behavioural intervention to promote regular self-weighing to prevent weight
43 regain after weight loss: a RCT. *Public Health Res.* 2019 May 1;7(7):1–66.
44
45
- 46 33. Morrell C, Spiby H, Stewart P, Walters S, Morgan A. Costs and benefits of
47 community postnatal support workers: a randomised controlled trial. *Health
48 Technol Assess.* 2000 Apr 3;4(6).
49
50
- 51 34. Townsend J, Wolke D, Hayes J, Dave S, Rogers C, Bloomfield L, et al. Routine
52 examination of the newborn: the EMREN study. Evaluation of an extension of
53 the midwife role including a randomised controlled trial of appropriately trained
54 midwives and paediatric senior house officers. *Health Technol Assess.* 2004
55 Mar 30;8(14).
56
57
- 58 35. Lobban F, Akers N, Appelbe D, Iraci Capuccinello R, Chapman L, Collinge L, et
59 al. A web-based, peer-supported self-management intervention to reduce
60 distress in relatives of people with psychosis or bipolar disorder: the REACT
RCT. *Health Technol Assess.* 2020 Jul 1;24(32):1–142.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
36. Kinley H, Czoski-Murray C, George S, McCabe C, Primrose J, Reilly C, et al. Extended scope of nursing practice: a multicentre randomised controlled trial of appropriately trained nurses and pre-registration house officers in pre-operative assessment in elective general surgery. *Health Technol Assess*. 2001 Jun 15;5(20).
 37. Elliott RA, Payne K, Moore JK, Davies LM, Harper NJN, St Leger AS, et al. Which anaesthetic agents and techniques are cost-effective in day surgery? Literature review, national survey of practice and randomised controlled trial. *Health Technol Assess*. 2003 Mar 13;6(30).
 38. McDermott L, Wright AJ, Cornelius V, Burgess C, Forster AS, Ashworth M, et al. Enhanced invitation methods and uptake of health checks in primary care: randomised controlled trial and cohort study using electronic health records. *Health Technol Assess*. 2016 Nov 14;20(84):1–92.
 39. Williams CL, Weller S, Roberts L, Reading I, Cook A, Little L, et al. Timing of surgical intervention for developmental dysplasia of the hip: a randomised controlled trial (Hip 'Op). *Health Technol Assess*. 2017 Oct 25;21(63):1–84.
 40. Walters S, Simpson R, Jacques R. Sample Size Estimation for Trials and Other Two Group Comparisons. In: *SAGE Research Methods Cases* [Internet]. London; 2021. Available from: <https://www.doi.org/10.4135/9781529741636>

Table 1: Characteristics of the trials included in the review

Characteristic		n (%)
Trial Design (n=388)	Parallel	345 (89)
	Factorial	19 (5)
	Crossover	4 (1)
	Other ^A	20 (5)
Arms (n=388)	2	290 (75)
	3	61 (16)
	4	24 (6)
	>4	13 (3)
Clinical Area (n=388)	Mental Health	73 (19)
	Musculoskeletal, Orthopedics & Rheumatology	44 (11)
	Obstetrics & Gynaecology	32 (8)
	Respiratory	29 (7)
	Cardiovascular	24 (6)
	Cancer/Oncology	21 (5)
	Stroke	19 (5)
	Dermatology (including ulcers)	17 (4)
	Gastrointestinal	14 (4)
	Primary care	11 (3)
	Diabetes	11 (3)
	Urology	10 (3)
	Neurology	10 (3)
	Infectious Disease	8 (2)
Dentistry	5 (1)	
Other ^B	60 (15)	
Setting (n=388)	Hospital	219 (56)
	General Practice	55 (14)
	Mixed	61 (16)
	Community	34 (9)
	Other ^C	19 (5)
Intervention Type (n=388)	Pharmaceutical Intervention	111 (29)
	Complex Intervention	65 (17)
	Therapy	54 (14)
	Surgery	46 (12)
	Other ^D	112 (29)
Control Type (n=388)	Placebo	87 (22)
	Active	301 (78)
Patient Blinded (n=384)	Yes	100 (26)
	No	284 (74)
Centres outside the UK? (n=388)	Yes	33 (9)
	No	355 (91)
Geographical Spread (n=388)	Multiple Regions	317 (82)
	Regional	71 (18)
Some form of pilot? ^E (n=388)	Yes	194 (50)
	No	194 (50)

^A 2 or 3 parallel RCTs, cohort multiple RCT, patient preference/Zelen's

^B Alcohol abuse, allergy, chronic fatigue, cystic fibrosis, gerontology, hepatology, intensive care, minor surgery, multiple sclerosis, obesity/weight loss, nephrology, neurosurgery, nutrition, ophthalmology, otorhinolaryngology, paediatric (general, anaesthesiology, dermatology, nephrology, obesity/weight loss), physical exercise, rehabilitation, reproductive health resuscitation, septic shock, sleep disorders, speech therapy, vascular

^C Bowel Cancer Screening Programme, Exercise Schemes, Football Clubs, HIV Clinics, Intellectual Disability Services, Leisure Centres, Mobile Dental Clinics, Online, Physical Therapy Classes, Prison, Public School, Sexual Health Clinics, Specialist Care Centres, Stop Smoking Services, University Clinics

^D Advice and Information, Consultation, Diagnostic Information, Drug vs Surgery, Equipment, Health Professional, Patient Pathway, Technique

^E Any mention of pilot work or feasibility study recorded.

Table 2: Recruitment and sample size characteristics of the trials included in the review

Characteristic (n = 388)	n (%)	Mean (SD)	Median (IQR)	Range	
Number of Centres	1	25 (6)	29	17	1 - 274
	2-5	61 (16)	(34)	(7 - 37)	
	6-10	48 (12)			
	11-20	69 (18)			
	21-50	112 (29)			
	51-100	48 (12)			
	> 100	16 (4)			
Missing	9 (2)				
Original Target Recruitment	≤ 200	49 (13)	1,097	500	50 - 46,000
	201-400	101 (26)	(3,080)	(300 - 900)	
	401-600	86 (22)			
	601-800	41 (11)			
	> 800	109 (28)			
Missing	2 (1)				
Final Target Recruitment	≤ 200	53 (14)	1,041	480	44 - 46,000
	201-400	112 (29)	(3,074)	(270 - 802)	
	401-600	84 (22)			
	601-800	42 (11)			
	> 800	97 (25)			
Final Total Recruitment	≤ 200	72 (19)	991	452	2 - 47,062
	201-400	99 (26)	(3,025)	(236 - 800)	
	401-600	82 (21)			
	601-800	39 (10)			
	> 800	96 (25)			
Final Recruitment Target Achieved	Yes	245 (63)			
	No, but with ≥ 80% of target	86 (22)			
	No, < 80% of target	57 (15)			
Timing of Primary Outcome Follow-Up (months post-randomisation)	≤ 1 month	42 (11)	12	10	0 - 120
	1 < months ≤ 6	129 (33)	(13)	(3 - 12)	
	6 < months ≤ 18	131 (34)			
	> 18 months	63 (16)			
	Missing	23 (6)			
Timing of Final Follow-Up (months post-randomisation)	≤ 1 month	20 (5)	16	12	0.066 - 144
	1 < months ≤ 6	87 (22)	(19)	(6 - 18)	
	6 < months ≤ 18	181 (47)			
	> 18 months	88 (23)			
	Missing	12 (3)			

Table 3: Data completeness in relation to CONSORT guidelines and recruitment information

Trial Characteristic (N=388)	n (%)
Number Screened	327 (84)
Number eligible	309 (80)
Number refused/declined consent	282 (73)
Total recruitment	388 (100)
Number included in primary analysis (retention)	388 (100)
Number of centres	379 (98)
Maximum recruitment length	369 (95)
Centre-specific recruitment length	97 (25)
Recruitment rate can be calculated	365 (94)

CONSORT, Consolidated Standards of Reporting Trials

For peer review only

Table 4: Overall consent, recruitment and retention rates and association with journal

	Journal	n	Median	IQR	Range	P-Value
Consent Rate (percentage of eligible participants consented and randomised)	All	309	72%	50 – 88%	4 – 100%	0.225 ^A
	HTA	230	72%	50 – 88%	4 – 100%	
	EME	36	74%	52 – 93%	11 – 100%	
	PGfAR	30	65%	48 – 84%	19 – 100%	
	HS&DR	7	81%	60 – 97%	35 – 100%	
	PHR	6	57%	40 – 68%	35 – 76%	
Recruitment Rate (participants recruited per centre per month)	All	365	0.95	0.42 – 2.60	0.01 – 57.75	0.010 ^A
	HTA	289	0.85	0.39 – 2.49	0.01 – 57.75	
	EME	39	1.18	0.45 – 2.46	0.15 – 18.61	
	PGfAR	25	1.18	0.53 – 2.80	0.07 – 24.03	
	HS&DR	6	1.88	1.71 – 10.82	1.69 – 18.87	
	PHR	6	7.62	1.79 – 17.06	1.69 – 20.57	
Retention Rate (percentage of randomised participants retained and assessed in primary outcome)	All	388	88%	80 – 97%	0 – 100%	0.118 ^A
	HTA	303	89%	80 – 97%	0 – 100%	
	EME	39	89%	80 – 97%	47 – 100%	
	PGfAR	31	84%	78 – 91%	43 – 100%	
	HS&DR	9	82%	73 – 89%	68 – 99%	
	PHR	6	85%	78 – 90%	74 – 92%	

^A P-Values are reported from a Kruskal-Wallis test

Table 5: Association between recruitment rate (number of participants/centre/month) and trial characteristics

Characteristic (n=365)		n	Median	IQR	P-Value
Setting	Hospital	212	0.90	0.4 - 2.29	0.009 ^{A,B}
	General Practice	51	0.71	0.32 - 1.18	
	Mixed	56	1.01	0.47 - 2.64	
	Community	29	2.44	0.62 - 6.41	
	Other	17	1.89	0.76 - 11.7	
Arms	2	278	1.10	0.41 - 2.76	0.935 ^C
	3	55	0.85	0.45 - 2.1	
	4	22	1.04	0.57 - 1.91	
	>4	10	0.85	0.42 - 8.85	
Control Type	Placebo	85	0.84	0.38 - 1.93	0.145 ^D
	Active	280	1.03	0.43 - 3.22	
Original Target Recruitment	≤ 200	41	1.18	0.47 - 2.65	0.008 ^C
	201-400	93	0.78	0.36 - 2.01	
	401-600	84	0.84	0.43 - 1.96	
	601-800	40	1.13	0.46 - 2.88	
	> 800	105	1.49	0.55 - 4.72	
Final Target Recruitment	≤ 200	45	0.89	0.27 - 2.55	<0.001 ^C
	201-400	103	0.76	0.34 - 1.96	
	401-600	83	0.86	0.44 - 2.26	
	601-800	41	1.17	0.57 - 4.23	
	> 800	93	1.66	0.58 - 5.17	
Total Recruitment	≤ 200	63	0.50	0.17 - 1.6	<0.001 ^C
	201-400	90	0.78	0.37 - 2.07	
	401-600	81	1.15	0.49 - 2.41	
	601-800	39	1.03	0.57 - 3.85	
	> 800	92	1.96	0.68 - 6.23	
Timing of Final Follow-Up	≤ 1 month	19	1.29	0.42 - 2.26	0.054 ^C
	1 < months ≤ 6	82	1.14	0.38 - 4.14	
	6 < months ≤ 18	170	0.98	0.46 - 2.33	
	> 18 months	85	0.71	0.36 - 2.02	

^A The category 'other' was not included in Kruskal-Wallis test

^B P-Values are reported from a Kruskal-Wallis test

^C P-Values are reported from a Jonckheere-Terpstra test

^D P-Values are reported from a Mann-Whitney U test

Table 6: Association between the trial retention rate (% of randomised participants with valid primary outcome data for analysis) and trial characteristics

Characteristic (n=388)	n	Median	IQR	P-Value	
Setting	Hospital	219	91.5	82.2 - 97.8	0.001 ^{A,B}
	General Practice	55	84.0	76.6 - 91.3	
	Mixed	61	87.3	79.7 - 97.3	
	Community	34	84.9	75.4 - 90.8	
	Other	19	84.2	74.9 - 96.5	
Arms	2	290	89.9	81 - 97.4	<0.001 ^C
	3	61	84.4	72.4 - 93.6	
	4	24	83.2	79.6 - 88.2	
	>4	13	80.2	73.4 - 96.4	
Control Type	Placebo	87	89.8	79.1 - 97.3	0.614 ^D
	Active	301	87.8	80.3 - 96.4	
Final Target Recruitment	≤ 200	53	88.6	79.6 - 96.4	0.003 ^C
	201-400	112	86.1	77.1 - 94.1	
	401-600	84	86.8	78.9 - 95.7	
	601-800	42	84.4	80.4 - 90.9	
	> 800	97	96.3	85.3 - 99.1	
Total Recruitment	≤ 200	72	87.9	74.5 - 96.2	0.001 ^C
	201-400	99	87.3	79.3 - 94.9	
	401-600	82	86.4	80.6 - 94.1	
	601-800	39	86.2	82.2 - 91.4	
	> 800	96	95.8	82.4 - 99	
Timing of Final Follow-Up	≤ 1 month	20	92.2	78.7 - 99	0.518 ^C
	1 < months ≤ 6	87	88.5	79.8 - 96.7	
	6 < months ≤ 18	181	88.2	79.5 - 96.4	
	> 18 months	88	87.8	80 - 95.5	

^A The category 'other' was not included in Kruskal-Wallis test

^B P-Values are reported from a Kruskal-Wallis test

^C P-Values are reported from a Jonckheere-Terpstra test

^D P-Values are reported from a Mann-Whitney U test

Table 7: Comparison of the current review with three previous reviews in terms of successful recruitment to target sample size and extensions to recruitment

Review	McDonald <i>et al.</i>(7)	Sully <i>et al.</i>(5)	Walters <i>et al.</i>(8)	This study	This study
Recruitment period	1994-2002	2002-2008	2004-2016	2017-2020	1997-2020
Number of trials in the study	N = 122	N = 73	N = 151	N = 174	N = 388
Recruited 100% of original target	38 of 122 (31%)	40 of 73 (55%)	61 of 151 (40%)	107 of 174 (61%)	207 of 388 (53%)
Original target was revised	42 of 122 (34%)	14 of 73 (19%)	52 of 151 (34%)	54 of 174 (31%)	118 of 388 (30%)
Original target revised upward	6 of 42 (14%)	5 of 14 (36%)	11 of 52 (21%)	23 of 54 (43%)	39 of 118 (33%)
Original target revised downward	36 of 42 (86%)	9 of 14 (64%)	41 of 52 (79%)	31 of 54 (57%)	79 of 118 (67%)
Recruited 80% of original target	67 of 122 (55%)	57 of 73 (78%)	95 of 151 (63%)	139 of 174 (80%)	288 of 388 (74%)
Recruited 100% of revised target	19 of 42 (45%)	10 of 14 (71%)	28 of 52 (54%)	35 of 54 (65%)	80 of 118 (68%)
Recruited 80% of revised target	34 of 42 (80%)	13 of 14 (93%)	48 of 52 (92%)	48 of 54 (89%)	107 of 118 (91%)
Extended their recruitment	65 of 122 (54%)	33 of 73 (45%)	49 of 151 (32%)	65 of 174 (37%)	128 of 388 (33%)

Figure Legends

1
2
3 **Figure 1:** Flow diagram of search and selection process of individually RCTs from the five NIHR
4 journals between 1 January 1997 and 31 December 2020
5
6

7 **Figure 2:** Boxplots of recruitment rates by clinical area
8
9

10
11 **Figure 3:** Number of trials and percentage of trials recruiting 100% and $\geq 80\%$ of the final sample
12 size target from 1997 to 2020
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1: Flow diagram of search and selection process of individually RCTs from the five NIHR journals between 1 January 1997 and 31 December 2020

388x375mm (118 x 118 DPI)




Figure 2: Boxplots of recruitment rates by clinical area

228x152mm (300 x 300 DPI)




Figure 3: Number of trials and percentage of trials recruiting 100% and ≥80% of the final sample size target from 1997 to 2020

228x152mm (300 x 300 DPI)



PRISMA 2020 Checklist

36/bmjopen-2021-059230 on 14 February 2022. Downloaded from <http://bmjopen.bmj.com/> on 05 April 2022. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page 1 (title indicates this this a review)
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Pages 2 & 3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Pages 5 & 6
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 6
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Pages 6 & 7
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Pages 6 & 7
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Page 7
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Page 8
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Page 8
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Pages 8 & 9
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Page 8 & 9
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	NA
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	The primary outcome (recruitment rate) is described on pages 8 & 9.
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	NA
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Analysis methods are described

36/bmjopen-2021-059230 on 14 February 2022. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.



PRISMA 2020 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section and Topic	Item #	Checklist item	Location where item is reported
			on pages 8 & 9.
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Analysis methods are described on pages 8 & 9.
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Analysis methods are described on pages 8 & 9.
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	NA
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	NA
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	NA
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	NA
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	NA
Study characteristics	17	Cite each included study and present its characteristics.	NA
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	NA
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	NA
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	NA
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Results are described on pages 10 to 12; and in Tables 1 to 7
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	NA



PRISMA 2020 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section and Topic	Item #	Checklist item	Location where item is reported
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	NA
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	NA
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	NA
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Pages 13 & 14
	23b	Discuss any limitations of the evidence included in the review.	Pages 13 & 14
	23c	Discuss any limitations of the review processes used.	Page 14
	23d	Discuss implications of the results for practice, policy, and future research.	Pages 13 & 14
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	NA
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	NA
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	NA
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 14
Competing interests	26	Declare any competing interests of review authors.	Page 15
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Page 15

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>

36/bmjopen-2021-059230 on 14 February 2022. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.